Targeting HSP90 for cancer therapy
Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Jennifer S. Carew(University of Arizona), Ronan Swords(University of Miami), Steffan T. Nawrocki(University of Arizona), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center)
Cited by 320
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
|Journal of Biological Chemistry|2005|749